P. Tanswell

2.5k total citations
51 papers, 1.6k citations indexed

About

P. Tanswell is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, P. Tanswell has authored 51 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in P. Tanswell's work include Blood properties and coagulation (12 papers), Protease and Inhibitor Mechanisms (11 papers) and Acute Myocardial Infarction Research (11 papers). P. Tanswell is often cited by papers focused on Blood properties and coagulation (12 papers), Protease and Inhibitor Mechanisms (11 papers) and Acute Myocardial Infarction Research (11 papers). P. Tanswell collaborates with scholars based in Germany, United States and United Kingdom. P. Tanswell's co-authors include E. Seifried, Robert J. P. Williams, Nishit B. Modi, Thierry Danays, Dan Combs, Edward W. Westhead, Werner Feuerer, A. Amelsberg, Ralf‐Dieter Hofheinz and Erhard Seifried and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Biochemical Journal.

In The Last Decade

P. Tanswell

50 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Tanswell Germany 20 434 369 360 320 301 51 1.6k
Jean–Marie Stassen Belgium 22 802 1.8× 316 0.9× 216 0.6× 436 1.4× 602 2.0× 41 2.4k
W. Heller Germany 15 349 0.8× 389 1.1× 94 0.3× 390 1.2× 275 0.9× 81 1.5k
Eiichi Shiba Japan 20 427 1.0× 253 0.7× 83 0.2× 292 0.9× 93 0.3× 96 1.7k
David Chu United States 27 1.1k 2.5× 1.1k 2.9× 147 0.4× 428 1.3× 274 0.9× 56 2.8k
Brigitte Kaiser Germany 17 315 0.7× 153 0.4× 162 0.5× 103 0.3× 400 1.3× 61 1.6k
P. Hilgard Germany 24 678 1.6× 377 1.0× 113 0.3× 195 0.6× 62 0.2× 81 1.6k
John Wang United States 22 519 1.2× 314 0.9× 287 0.8× 221 0.7× 95 0.3× 81 1.4k
Iris Müller Germany 20 333 0.8× 225 0.6× 231 0.6× 103 0.3× 1.2k 4.1× 34 2.3k
E Bastida Spain 21 352 0.8× 229 0.6× 50 0.1× 140 0.4× 254 0.8× 62 1.3k
Stanley J. Hollenbach United States 20 469 1.1× 211 0.6× 116 0.3× 121 0.4× 797 2.6× 40 2.0k

Countries citing papers authored by P. Tanswell

Since Specialization
Citations

This map shows the geographic impact of P. Tanswell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Tanswell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Tanswell more than expected).

Fields of papers citing papers by P. Tanswell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Tanswell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Tanswell. The network helps show where P. Tanswell may publish in the future.

Co-authorship network of co-authors of P. Tanswell

This figure shows the co-authorship network connecting the top 25 collaborators of P. Tanswell. A scholar is included among the top collaborators of P. Tanswell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Tanswell. P. Tanswell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guth, Brian D., et al.. (2004). Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. British Journal of Clinical Pharmacology. 58(1). 40–51. 8 indexed citations
2.
Kloft, Charlotte, P. Tanswell, Andrew M. Scott, et al.. (2003). Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients. Investigational New Drugs. 22(1). 39–52. 47 indexed citations
3.
Hofheinz, Ralf‐Dieter, Salah‐Eddin Al‐Batran, Frank Hartmann, et al.. (2003). Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer. Oncology Research and Treatment. 26(1). 44–48. 289 indexed citations
4.
Tanswell, P., Nishit B. Modi, Dan Combs, & Thierry Danays. (2002). Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction. Clinical Pharmacokinetics. 41(15). 1229–1245. 190 indexed citations
5.
Tanswell, P., Pilar Garin‐Chesa, Wolfgang J. Rettig, et al.. (2001). Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51(2). 177–180. 1 indexed citations
6.
Tanswell, P., Pilar Garin‐Chesa, Wolfgang J. Rettig, et al.. (2001). Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. British Journal of Clinical Pharmacology. 51(2). 177–180. 37 indexed citations
7.
Modi, Nishit B., Norma Lynn Fox, P. Tanswell, et al.. (2000). Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction. The Journal of Clinical Pharmacology. 40(5). 508–515. 41 indexed citations
8.
Danays, Thierry, et al.. (1998). A Simple, Incremental Weight-Adjusted Dosing Scheme for TNK-tPA, A Bioengineered Variant of the Natural t-PA Molecule. Circulation. 98(17).
9.
Godfrey, K.R., et al.. (1998). Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models. Biopharmaceutics & Drug Disposition. 19(2). 131–140. 15 indexed citations
10.
Gulba, Dietrich C., P. Tanswell, Ralf Dechend, et al.. (1997). Sixty-Minute Alteplase Protocol: A New Accelerated Recombinant Tissue-Type Plasminogen Activator Regimen for Thrombolysis in Acute Myocardial Infarction. Journal of the American College of Cardiology. 30(7). 1611–1617. 20 indexed citations
11.
Tanswell, P., et al.. (1992). Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. Journal of the American College of Cardiology. 19(5). 1071–1075. 102 indexed citations
12.
Seifried, E., et al.. (1992). Studies on the functionality of fibrinogen during rt-PA therapy. Blood Coagulation & Fibrinolysis. 3(1). 81–88. 9 indexed citations
13.
Tanswell, P., E. Seifried, Espen Stang, & J. Krause. (1991). Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator.. PubMed. 41(12). 1310–9. 41 indexed citations
14.
Tanswell, P., et al.. (1990). Absolute bioavailability of pirenzepine in intensive care patients. European Journal of Clinical Pharmacology. 38(3). 265–268. 6 indexed citations
15.
Tanswell, P., et al.. (1989). Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. European Journal of Clinical Pharmacology. 36(1). 75–78. 13 indexed citations
16.
Tanswell, P., et al.. (1989). Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clinical Pharmacology & Therapeutics. 46(2). 155–162. 64 indexed citations
17.
Londong, W, et al.. (1989). Pharmacokinetic and pharmacodynamic studies in man simulating acute and chronic treatment with oral pirenzepine. European Journal of Clinical Pharmacology. 36(4). 369–374. 1 indexed citations
18.
Tebbe, Ulrich, et al.. (1989). Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. The American Journal of Cardiology. 64(8). 448–453. 72 indexed citations
19.
Tanswell, P., et al.. (1989). Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renaland hepatic insufficiency. European Journal of Clinical Pharmacology. 36(1). 71–73. 5 indexed citations
20.
Tanswell, P., et al.. (1977). Immunochemistry of bovine fibrinogen—III. Immunochemistry. 14(4). 277–281. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean–Marie Stassen Breakdown of academic impact, for papers by W. Heller Breakdown of academic impact, for papers by Eiichi Shiba Breakdown of academic impact, for papers by David Chu Breakdown of academic impact, for papers by Brigitte Kaiser Breakdown of academic impact, for papers by P. Hilgard Breakdown of academic impact, for papers by John Wang Breakdown of academic impact, for papers by Iris Müller Breakdown of academic impact, for papers by E Bastida Breakdown of academic impact, for papers by Stanley J. Hollenbach
Rankless by CCL
2026